Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 PHARMACOKINETIC-PHARMACODYNAMIC STUDY OF AVELUMAB (MSB0010718C) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED STAGE CLASSICAL HODGKIN'S LYMPHOMA

NCT02603419 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02603419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02603419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 PHARMACOKINETIC-PHARMACODYNAMIC STUDY OF AVELUMAB (MSB0010718C) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED STAGE CLASSICAL HODGKIN'S LYMPHOMA
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
March 10, 2016
Completion date
April 11, 2019
Enrollment
34 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkins lymphoma